[go: up one dir, main page]

AR110125A1 - Compuestos poliméricos que liberan sulfuro de hidrógeno - Google Patents

Compuestos poliméricos que liberan sulfuro de hidrógeno

Info

Publication number
AR110125A1
AR110125A1 ARP170103071A ARP170103071A AR110125A1 AR 110125 A1 AR110125 A1 AR 110125A1 AR P170103071 A ARP170103071 A AR P170103071A AR P170103071 A ARP170103071 A AR P170103071A AR 110125 A1 AR110125 A1 AR 110125A1
Authority
AR
Argentina
Prior art keywords
hydrogen sulfide
compound
polymeric compounds
release hydrogen
side chain
Prior art date
Application number
ARP170103071A
Other languages
English (en)
Inventor
Hoffer Martin Dr
Martin Prinz
Original Assignee
Croma Pharma Ges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Croma Pharma Ges M B H filed Critical Croma Pharma Ges M B H
Publication of AR110125A1 publication Critical patent/AR110125A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/733—Alginic acid; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • C08F251/02—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof on to cellulose or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Se proporciona un polímero que libera sulfuro de hidrógeno que tiene un esqueleto de polisacárido y sus usos. Además, se proporciona un método de tratamiento y prevención de una afección cutánea, una enfermedad ocular u osteoartritis. Reivindicación 6: Un compuesto según la reivindicación 1 o la reivindicación 5 o un compuesto para uso según una cualquiera de las reivindicaciones 2 a 5, caracterizado porque el compuesto tiene un esqueleto polimérico y al menos una cadena lateral y en el que la cadena lateral comprende una subestructura de acuerdo con la fórmula (1) en la que R¹ es un grupo alquilo, alquenilo, alquinilo, alquilarilo, aralquilo o arilo, seleccionado preferiblemente del grupo que consiste en fenilo o metilo, y en el que el cuadrado indica el punto de unión de la subestructura.
ARP170103071A 2016-11-07 2017-11-06 Compuestos poliméricos que liberan sulfuro de hidrógeno AR110125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16197625 2016-11-07

Publications (1)

Publication Number Publication Date
AR110125A1 true AR110125A1 (es) 2019-02-27

Family

ID=57345687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103071A AR110125A1 (es) 2016-11-07 2017-11-06 Compuestos poliméricos que liberan sulfuro de hidrógeno

Country Status (13)

Country Link
US (2) US11331338B2 (es)
EP (1) EP3534886A1 (es)
JP (1) JP2020500953A (es)
KR (1) KR20190083332A (es)
CN (1) CN109922797A (es)
AR (1) AR110125A1 (es)
BR (1) BR112019008230A2 (es)
CA (1) CA3042137A1 (es)
IL (1) IL266487B (es)
MA (1) MA46699A (es)
MX (1) MX2019005165A (es)
RU (1) RU2768716C2 (es)
WO (1) WO2018083326A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
BR112020024654B1 (pt) 2018-06-15 2024-02-27 Croma-Pharma Gmbh Composição de hidrogel estéril, unidade de aplicação para injeção,seus usos, método cosmético, enchimento de tecido mole, e implante ou depósito
BR112020024637B1 (pt) 2018-06-15 2024-01-30 Croma-Pharma Gmbh Composição de hidrogel estéril, seus usos, enchimento de tecido macio, e implante ou depósito
CN109678987B (zh) * 2018-12-03 2020-12-25 河南大学 一种硫化氢释放剂ha-adt、其制备方法及应用
CN110279610B (zh) * 2019-06-26 2021-06-11 常州百瑞吉生物医药有限公司 一种透明质酸皮肤保护组合物及其制备方法和应用
CN114072156A (zh) 2019-06-28 2022-02-18 国立研究开发法人物质·材料研究机构 皮肤创伤预防用和/或皮肤创伤治疗用构成体
FR3098723B1 (fr) * 2019-07-18 2023-01-13 Bionuclei Traitement ecobiologique des effets secondaires de la radiotherapie.
KR102209574B1 (ko) * 2019-10-08 2021-02-01 주식회사 에스엔비아 싸이올 화합물 소취용 조성물
CN114787199B (zh) * 2019-12-19 2023-06-20 克罗马药品有限责任公司 硫醇修饰的透明质酸和包含交联透明质酸的水凝胶
CN111228223B (zh) * 2020-03-06 2021-06-18 同济大学 一种促进伤口愈合的聚合物囊泡及其制备方法和应用
CN111777711B (zh) * 2020-07-29 2022-02-08 南京邮电大学 一种光热控制释放硫化氢的聚合物及其制备方法和应用
CN113855851B (zh) * 2021-09-24 2023-03-31 广东省科学院健康医学研究所 一种水凝胶及其制备方法和应用
CN119326944B (zh) * 2024-10-23 2026-01-30 西北工业大学 一种自供应硫化氢的促伤口愈合抗菌水凝胶伤口敷料及其制备方法和应用
CN121248644A (zh) * 2025-12-08 2026-01-02 河套学院 一种活性氧响应的硫化氢供体、活性氧响应硫化氢可控释放型阳离子化壳聚糖海绵及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US6261594B1 (en) * 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
WO2006119258A2 (en) 2005-04-29 2006-11-09 University Of Houston Use of hydrogen sulfide in the treatment of eye diseases
US7498355B2 (en) 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
CN101622017B (zh) * 2006-12-22 2018-09-11 克罗马制药有限责任公司 聚合物的用途
ITMI20071341A1 (it) 2007-07-05 2009-01-06 Fidia Farmaceutici Derivati di acido ialuronico contenenti gruppi in grado di rilasciare no
ITMI20080382A1 (it) 2008-03-07 2009-09-08 Ctg Pharma S R L Composizioni farmaceutiche oculari
US20100136070A1 (en) 2008-12-03 2010-06-03 Jakk Group, Inc. Methods, devices, and compositions for dermal filling
US20100198338A1 (en) 2009-01-30 2010-08-05 Medtronic Vascular, Inc., A Delaware Corporation Hydrogen Sulfide Donating Polymers
EP2482852B1 (de) 2009-09-30 2017-11-22 ThioMatrix Forschungs- und Beratungs GmbH Mukoadhäsive polymere mit vitamin b-teilstrukturen
US8182830B2 (en) 2010-01-05 2012-05-22 Medtronic Vascular, Inc. Hydrogen sulfide generating polymers
BR112012024887A2 (pt) 2010-04-08 2016-06-21 Merz Pharma Gmbh & Co Kgaa grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
WO2012075242A2 (en) 2010-12-01 2012-06-07 Washington State University Research Foundation Controlled chemical release of hydrogen sulfide
RS59383B1 (sr) 2014-05-07 2019-11-29 Croma Pharma Ges M B H Vodeni oftalmološki rastvor i postupak za lečenje sindroma suvog oka
CN108040479B (zh) 2015-04-03 2021-08-03 乔治亚州立大学研究基金会股份有限公司 硫化氢前体及其偶联物

Also Published As

Publication number Publication date
JP2020500953A (ja) 2020-01-16
US20190298756A1 (en) 2019-10-03
RU2019117549A3 (es) 2021-03-12
RU2768716C2 (ru) 2022-03-24
MX2019005165A (es) 2019-08-05
BR112019008230A2 (pt) 2019-07-09
WO2018083326A1 (en) 2018-05-11
US11331338B2 (en) 2022-05-17
EP3534886A1 (en) 2019-09-11
RU2019117549A (ru) 2020-12-07
CA3042137A1 (en) 2018-05-11
IL266487A (en) 2019-07-31
IL266487B (en) 2022-01-01
MA46699A (fr) 2019-09-11
US20220233579A1 (en) 2022-07-28
KR20190083332A (ko) 2019-07-11
CN109922797A (zh) 2019-06-21

Similar Documents

Publication Publication Date Title
AR110125A1 (es) Compuestos poliméricos que liberan sulfuro de hidrógeno
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
BR112018004620A2 (pt) moduladores da expressão de kras
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
MX374399B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
CR20160477A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
BR112017004393A2 (pt) formulações de anticorpo
CL2017000014A1 (es) Derivados de isondolina para su uso en el tratamiento de una infección viral
AR104342A1 (es) Compuesto heterocíclico
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
BR112017000849A2 (pt) composição antiaderente
BR112016024238A2 (pt) uso de composições aquosas de redução de desvio
TN2018000351A1 (en) Oxaborole esters and uses thereof
MX2015018028A (es) Composiciones de lagrimas artificiales.
CL2017000151A1 (es) Derivados de piridona
MX390448B (es) Composicion adhesiva.
AR104488A1 (es) Alcoxilatos de alcohol de intervalo estrecho y derivados de estos
BR112017020216A2 (pt) ?composição aquosa?.

Legal Events

Date Code Title Description
FB Suspension of granting procedure